News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Cladribine Tablets: Observational Evaluation Of Effectiveness And Patient-Reported Outcomes (Pros) In Suboptimally Controlled Patients Previously Taking Oral Or Infusion Disease Modifying Drugs (Dmds) For Relapsing Forms Of Multiple Sclerosis (RMS) (MASTER-2)

Study Status:

Not Yet Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of the MASTER-2 study is to evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS), who transition to cladribine tablets after suboptimal response to any oral or infusion Disease-Modifying Drugs (DMDs) approved in the United States (US) for RMS in a real-world-setting.

Information: 

Principal Investigator
Roberto A. Cruz Saldana, M.D.
Sponsor
EMD Serono
Type of Trial
Observational
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram